CORE
CO
nnecting
RE
positories
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Research partnership
About
About
About us
Our mission
Team
Blog
FAQs
Contact us
Community governance
Governance
Advisory Board
Board of supporters
Research network
Innovations
Our research
Labs
Predictors of alternative antidepressant agent initiation among U. S. veterans diagnosed with depression
Authors
Karen E. Downing
Dara Ganoczy
+6 more
Katherine Hoggatt
Hyungjin Myra Kim
John F. McCarthy
Paul N. Pfeiffer
Marcia Valenstein
Kara Zivin
Publication date
13 July 2010
Publisher
John Wiley & Sons, Ltd.
Doi
View
on
PubMed
Abstract
OBJECTIVES Naturalistic studies comparing differences in risks across antidepressant agents must take into account factors which influence selection of specific agents and may be associated with outcomes. We examined predictors of antidepressant choice among VA patients treated for depression. METHODS Retrospective cohort study of VA patients with depression diagnoses and a new start of one of the seven most commonly prescribed antidepressant agents between 1 April 1999 and 30 September 2004 ( n = 502 179). We examined the relationship between patient and facility characteristics and new starts of bupropion, citalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and venlafaxine. We also examined factors associated with new starts only among patients starting selective serotonin reuptake inhibitors (SSRIs). RESULTS Thirty-three percent of patients starting mirtazapine had at least three outpatient mental health visits in the prior year, compared to ≤24% of patients prescribed other antidepressants. Patients starting mirtazapine were also most likely to have received at least two other psychotropic medications in the prior year. Of the four SSRIs, 40% of the patients receiving sertraline and only 31% of those receiving fluoxetine were 65 years or older. A comorbid anxiety disorder (other than post-traumatic stress disorder) was diagnosed in 21% of paroxetine patients compared with ≤15% of other SSRI patients. CONCLUSION Choice of antidepressant medication for depressed VA patients was associated with important differences in demographic and clinical variables, including psychiatric illness severity, older age, and likelihood of a comorbid anxiety disorder. These findings emphasize the importance of controlling for selection bias when using observational data to compare risks from or effect of mental health treatments. Copyright © 2010 John Wiley & Sons, Ltd.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/78075/1/1985_ftp.pd
Similar works
Full text
Available Versions
Deep Blue Documents
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:deepblue.lib.umich.edu:202...
Last time updated on 25/05/2012
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1002%2Fpds.1985
Last time updated on 22/03/2019